Showing 2630 results
- https://www.novartis.com/news/media-releases/novartis-drug-zykadia-receives-fda-priority-review-first-line-use-patients-alk-metastatic-nsclcPriority Review based on Phase III study results showing 16.6 month median progression-free survival in previously untreated ALK+ metastatic NSCLC patients on Zykadia vs. 8.1 months treated with…
- https://www.novartis.com/news/media-releases/sandoz-pharmaceuticals-ag-recu-la-certification-top-employer-suisse-2017Sandoz Pharmaceuticals AG a été officiellement certifiée par le Top Employers Institute pour les conditions de travail exceptionnelles qu'elle offre à ses employés en SuisseL'étude internationale…
- https://www.novartis.com/news/media-releases/sandoz-pharmaceuticals-ag-als-top-arbeitgeber-schweiz-2017-ausgezeichnetSandoz Pharmaceuticals AG wurde offiziell vom Top Employers Institute für ihr hervorragendes Mitarbeiterangebot in der Schweiz ausgezeichnet Die jährliche internationale Forschungstätigkeit des…
- https://www.novartis.com/news/media-releases/novartis-drug-votubia-receives-eu-approval-treat-refractory-partial-onset-seizures-patients-tscVotubia is the first adjunctive treatment approved in the EU specifically for partial-onset seizures in children and adults with tuberous sclerosis complex (TSC) Approval addresses unmet…
- https://www.novartis.com/news/media-releases/novartis-highlights-progress-towards-access-and-environmental-goals-2016-corporate-responsibility-performance-reportNovartis Access-to-medicine programs reached approximately 52 million patients, including first-year deliveries through the innovative Novartis Access program Novartis improved position in…
- https://www.novartis.com/news/media-releases/alcon-launches-new-trifocal-toric-intraocular-lens-patients-astigmatism-undergoing-cataract-surgeryInnovative AcrySof® IQ PanOptix® Toric intraocular lens (IOL) extends Alcon's trifocal PanOptix® IOL portfolio to a wider range of patients CE-marked in November 2016, this IOL offers…
- https://www.novartis.com/news/media-releases/novartis-delivered-solid-2016-performance-growth-products1-absorbing-gleevec-us-loe-innovation-momentum-continued-announces-share-buybackFY net sales (0% cc[2]) in line with prior year due to strong Growth Products performance Cosentyx (USD 1.1 billion) reached blockbuster status Entresto (USD 170 million) continued to grow…
- https://www.novartis.com/news/media-releases/sandoz-receives-positive-chmp-opinion-proposed-biosimilar-infliximabSandoz is seeking approval of biosimilar infliximab for use in all indications of its reference medicine across gastroenterology, rheumatology and dermatology Positive opinion is based on a…
- https://www.novartis.com/news/media-releases/phase-iii-data-lancet-show-novartis-siponimod-significantly-improves-outcomes-patients-secondary-progressive-msEXPAND shows oral siponimod (BAF312) is the first potential therapy to meaningfully delay disability progression in typical secondary progressive MS (SPMS) patients Results demonstrate…
- https://www.novartis.com/news/media-releases/novartis-drug-tasigna-approved-fda-treat-children-rare-form-leukemiaTasigna® (nilotinib) approved for pediatric patients with newly diagnosed Ph+ CML-CP and children with Ph+ CML-CP resistant or intolerant to prior TKI therapy New indication approved under FDA…
Pagination
- ‹ Previous page
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- …
- 263
- › Next page